Sincalide ammonium
Based on 4 publication(s) in Google Scholar
Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK.
For research use only. We do not sell to patients.
- Purity : 99.21%
- CAS No.: 70706-98-8
- Formula: C49H65N11O16S3
- Molecular Weight:1160.30
-
Storage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sincalide ammonium
More
Customer Validation & Images
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
Biological Activity
Description
In Vitro
Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium), as a novel cardiovascular hormone, has a significant inhibitory effect on myocardial fibrosis in noninfarcted areas. Sincalide ammonium also plays a positive role in fighting inflammation, apoptosis and collagen deposition. CCK‐8 (ammonium) protects H9c2 cardiomyoblasts from Ang II‐induced apoptosis partly via activation of the CCK1 receptor and the phosphatidyqinositol‐3 kinase/protein kinase B (PI3K/Akt) signaling pathway[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:H9c2 cells
-
Concentration:0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
-
Incubation Time:24 h
-
Result:Attenuated Ang II‐induced toxicity in H9c2 cells
-
Cell Line:H9c2 cells
-
Concentration:0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
-
Incubation Time:24 h
-
Result:Decreased apoptotic cells, and prevented Ang II‐induced cytotoxicity that involves modulation of the PI3K/Akt pathway.
-
Cell Line:H9c2 cells
-
Concentration:0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
-
Incubation Time:24 h
-
Result:Expressed the protein and mRNAs of CCK and both its receptors in H9c2 cells.
-
Cell Line:H9c2 cells
-
Concentration:0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
-
Incubation Time:24 h
-
Result:Increased the protein and mRNA expression levels of CCK and decreased CCK 1 receptor expression levels at both the protein and mRNA levels with Ang II stimulation markedly.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MI rat model[4]
-
Dosage:50 μg/kg
-
Administration:i.p.; 50 μg/kg/d; for 4 weeks
-
Result:Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 70706-98-8
-
Appearance Solid
-
Molecular Weight 1160.30
-
Formula C49H65N11O16S3
-
Color White to off-white
-
Synonyms
Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium
-
Sequence Shortening
D-{SO3H-Tyr}-MGWMDF-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Antioxidants (Basel)
Identification of AP-1 as a Critical Regulator of Glutathione Peroxidase 4 (GPX4) Transcriptional Suppression and Acinar Cell Ferroptosis in Acute Pancreatitis. [Abstract]2022 Dec 31;12(1):100. PMID: 36670963
Sincalide ammonium purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2022 Dec 31;12(1):100. [Abstract]
After transfection with GPX4 siRNA, mouse pancreatic acinar carcinoma 266-6 cells were treated with Sincalide (Cholecystokinin; CCK) (5 μM; 6 h), and lipid reactive oxygen species (ROS) levels and the extent of cell death were determined.
-
J Gene Med
2025 Dec;27(12):e70063. PMID: 41340461
Sincalide ammonium purchased from MedChemExpress. Usage Cited in: J Gene Med. 2025 Dec;27(12):e70063. [Abstract]
Sincalide (Cholecystokinin; CCK) increased the expression of IL-6, TNF-α, and IL-1β in 266-6 cells.
-
Immunogenetics
IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma. [Abstract]2023 Feb;75(1):17-25. PMID: 36056935
Sincalide ammonium purchased from MedChemExpress. Usage Cited in: Immunogenetics. 2023 Feb;75(1):17-25. [Abstract]
Sincalide (CCK-8) (10 μL; 37 ℃; 2 h) was used to evaluate the proliferative ability of LUAD cells.
Sincalide ammonium purchased from MedChemExpress. Usage Cited in: Immunogenetics. 2023 Feb;75(1):17-25. [Abstract]
Sincalide (CCK-8) (10 μL; 37 ℃; 2 h) was used to illustrate that si-IL4I1 + RO8191 had the ability to reverse the restraining impact of si-IL4I1 on LUAD cell proliferation.
-
Biomed Pharmacother
Coupling the near-infrared fluorescent dye IR-780 with cabazitaxel makes renal cell carcinoma chemotherapy possible. [Abstract]2019 Aug:116:109001. PMID: 31146114
Sincalide ammonium purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2019 Aug:116:109001. [Abstract]
The OATP superfamily blocker Sincalide (SIN) (20 μM; 2 h) blocked Caba-780 uptake in renal cell carcinoma (RCC) cells.
Solvent & Solubility
In Vitro:
H2O : 33.33 mg/mL (28.73 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
Purity & Documentation
-
Data Sheet (291 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Maher KA. Kinevac (sincalide for injection)/Squibb Diagnostics. Gastroenterol Nurs. 1991 Oct;14(2):98-100. [Content Brief]
[2]. Ziessman HA. Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues. J Nucl Med Technol. 2019 Sep;47(3):210-212. [Content Brief]
[3]. Can Wang, et al. Protective effect of cholecystokinin octapeptide on angiotensin II-induced apoptosis in H9c2 cardiomyoblast cells. J Cell Biochem. 2020 Jul;121(7):3560-3569. [Content Brief]
[4]. Can Wang, et al. Cholecystokinin octapeptide reduces myocardial fibrosis and improves cardiac remodeling in post myocardial infarction rats. Int J Biochem Cell Biol. 2020 Aug;125:105793. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.8618 mL | 4.3092 mL | 8.6185 mL | 21.5462 mL |
| 5 mM | 0.1724 mL | 0.8618 mL | 1.7237 mL | 4.3092 mL | |
| 10 mM | 0.0862 mL | 0.4309 mL | 0.8618 mL | 2.1546 mL | |
| 15 mM | 0.0575 mL | 0.2873 mL | 0.5746 mL | 1.4364 mL | |
| 20 mM | 0.0431 mL | 0.2155 mL | 0.4309 mL | 1.0773 mL | |
| 25 mM | 0.0345 mL | 0.1724 mL | 0.3447 mL | 0.8618 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Sincalide ammonium Related Classifications
HY-P0093A Related Classifications
Powered by Bioz